SMLR - Semler Scientific: High-Quality Medical Stock With Cash Flow Growth And Zero Debt
This article was written by David Zanoni in collaboration with Risk Research Inc.
It is rare to find a company with ten years of above-average revenue growth, four years of operating cash flow growth and zero debt. Bought right, these stocks have the potential for major investment returns. Risk Research identifies companies with those characteristics, and then follows them, waiting for advantageous pricing. The software we’ve developed weighs the probabilities that a lower price will be achieved over the next twelve months with the potential that will be forgone if that price is not achieved.